DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Other Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other non-current liabilities remains negative
Q1 FY2026 other non-current liabilities was $0, compared with $0 a year earlier.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 other non-current liabilities of $0 is the 6th highest of the 7 companies compared; the peer median is $775.5K.
- Other non-current liabilities amounts to 0.0% of total assets for DMAC, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $205.19M | +1864.7% | +144.4% | 17.7% | |
| Mar 2026 | $161.26M | +10.6% | -65.3% | 44.5% | |
| Mar 2026 | $1.07M | +40.6% | +56.9% | 0.4% | |
BIOABioAge Labs, Inc. | Mar 2026 | $477K | +391.8% | -85.9% | 0.1% |
| Mar 2026 | $388K | -61.4% | — | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DMAC) | $775.5K | +40.6% | -4.2% | 0.2% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.